| 9.06 -0.29 (-3.1%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.19 |
1-year : | 12.54 |
| Resists | First : | 9.58 |
Second : | 10.73 |
| Pivot price | 8.76  |
|||
| Supports | First : | 7.71 |
Second : | 6.41 |
| MAs | MA(5) : | 9.35 |
MA(20) : | 8.67 |
| MA(100) : | 8.73 |
MA(250) : | 8.03 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.6 |
D(3) : | 54.2 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 11.97 | Low : | 6.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NVAX ] has closed below upper band by 40.2%. Bollinger Bands are 42.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.35 - 9.39 | 9.39 - 9.43 |
| Low: | 8.8 - 8.87 | 8.87 - 8.92 |
| Close: | 8.97 - 9.07 | 9.07 - 9.14 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Sun, 17 May 2026
Novavax Inc stock (US66987V1098): earnings volatility and Covid-vaccine hopes in focus - AD HOC NEWS
Sun, 17 May 2026
Novavax Inc stock (US6707721049): vaccine specialist in focus after latest COVID shot update - AD HOC NEWS
Fri, 15 May 2026
Shah Capital holds 9% Novavax stake and challenges board (NVAX) - Stock Titan
Fri, 15 May 2026
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Thu, 14 May 2026
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Wed, 13 May 2026
Vanguard Group Inc. Has $103.96 Million Position in Novavax, Inc. $NVAX - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 164 (M) |
| Shares Float | 140 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 68.1 (%) |
| Shares Short | 46,340 (K) |
| Shares Short P.Month | 48,630 (K) |
| EPS | 2.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.8 |
| Profit Margin | 39.1 % |
| Operating Margin | 14.2 % |
| Return on Assets (ttm) | 25.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 66.5 % |
| Gross Profit (p.s.) | 4.33 |
| Sales Per Share | 6.81 |
| EBITDA (p.s.) | 3.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -245 (M) |
| Levered Free Cash Flow | -332 (M) |
| PE Ratio | 3.51 |
| PEG Ratio | 1.3 |
| Price to Book value | -11.47 |
| Price to Sales | 1.33 |
| Price to Cash Flow | -6.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|